VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
VBIV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. VBIV may be in some trouble as it scores bad on both profitability and health. VBIV is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year VBIV has reported negative net income.
In the past year VBIV has reported a negative cash flow from operations.
In the past 5 years VBIV always reported negative net income.
VBIV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -111.34%, VBIV is doing worse than 80.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.34% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VBIV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VBIV has more shares outstanding
Compared to 5 years ago, VBIV has more shares outstanding
VBIV has a worse debt/assets ratio than last year.
2.2 Solvency
VBIV has an Altman-Z score of -13.90. This is a bad value and indicates that VBIV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.90, VBIV is not doing good in the industry: 83.22% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.9 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
A Current Ratio of 0.34 indicates that VBIV may have some problems paying its short term obligations.
VBIV's Current ratio of 0.34 is on the low side compared to the rest of the industry. VBIV is outperformed by 95.80% of its industry peers.
A Quick Ratio of 0.21 indicates that VBIV may have some problems paying its short term obligations.
VBIV has a Quick ratio of 0.21. This is amonst the worse of the industry: VBIV underperforms 97.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The earnings per share for VBIV have decreased strongly by -90.48% in the last year.
VBIV shows a strong growth in Revenue. In the last year, the Revenue has grown by 548.76%.
VBIV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.91% yearly.
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%
3.2 Future
The Earnings Per Share is expected to grow by 25.46% on average over the next years. This is a very strong growth
Based on estimates for the next years, VBIV will show a very strong growth in Revenue. The Revenue will grow by 64.62% on average per year.
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VBIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBIV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VBIV's earnings are expected to grow with 25.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.33%
EPS Next 3Y25.46%
5. Dividend
5.1 Amount
No dividends for VBIV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VBI VACCINES INC
NASDAQ:VBIV (8/7/2024, 8:00:02 PM)
After market: 0.045 -0.02 (-31.09%)0.0653
-0.07 (-50.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.03%
Inst Owner Change-99.7%
Ins Owners66.54%
Ins Owner Change0%
Market Cap1.87M
Analysts82.86
Price Target5.1 (7710.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.25%
Min EPS beat(2)-35.04%
Max EPS beat(2)95.54%
EPS beat(4)1
Avg EPS beat(4)-169%
Min EPS beat(4)-607.28%
Max EPS beat(4)95.54%
EPS beat(8)1
Avg EPS beat(8)-125.37%
EPS beat(12)4
Avg EPS beat(12)-83.31%
EPS beat(16)5
Avg EPS beat(16)-65.27%
Revenue beat(2)0
Avg Revenue beat(2)-71.33%
Min Revenue beat(2)-84.4%
Max Revenue beat(2)-58.27%
Revenue beat(4)0
Avg Revenue beat(4)-54.42%
Min Revenue beat(4)-84.4%
Max Revenue beat(4)-24.02%
Revenue beat(8)0
Avg Revenue beat(8)-59.02%
Revenue beat(12)1
Avg Revenue beat(12)-48.87%
Revenue beat(16)1
Avg Revenue beat(16)-48.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.8
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.33
BVpS-0.19
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.34% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.73% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z | -13.9 |
F-Score4
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)120.98%
Cap/Depr(5y)145.88%
Cap/Sales(3y)243.1%
Cap/Sales(5y)197.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A
EBIT growth 1Y44.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.15%
OCF growth 3YN/A
OCF growth 5YN/A